Yoshikazu Ito

Yoshikazu Ito

Auto-generated profile, based on publicly available information

Yoshikazu Ito

Department of Hematology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2007 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
YIYoshikazu Ito
Yoshikazu Ito
KOKazuma Ohyashiki
Kazuma Ohyashiki
IYIsao Yoshida
Isao Yoshida
MTMakoto Takeuchi
Makoto Takeuchi
YAYasutaka Aoyama
Yasutaka Aoyama
TGThe Japan Febrile Neutropenia Study Group
The Japan Febrile Neutropenia Study Group
We performed a randomized, controlled study comparing the prophylactic effects of capsule forms of fluconazole (n = 110) and itraconazole (n = 108) in patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) during and after chemotherapy.There were 4 cases with possible systemic fungal infection in the itraconazole group, and there were 8 possible and 3 probable cases in the fluconazole group. Adverse events did not significantly differ in the 2 groups. In patients with MDS or in the remission-induction phase of chemotherapy, the numbers of cases with probable or possible infections were lower in the itraconazole group than in the fluconazole group, whereas no difference was seen in patients with AML or in the consolidation phase of therapy. In patients with neutrophil counts of <0.1 * 109/L lasting for more than 4 weeks, the frequency of infection in the fluconazole group (5 of 9 patients) was significantly higher than in the itraconazole group (0 of 7 patients; P = .03). Our results suggest that both drugs were well tolerated in patients with AML or MDS who received chemotherapy and that the efficacy of itraconazole for prophylaxis against systemic fungal disease is not inferior to that of fluconazole.

31 March 2009 in Leukemia Research
Verified
Journal Article
Closed access
PDF file
TKToru Kiguchi
Toru Kiguchi
TTTetsuzo Tauchi
Tetsuzo Tauchi
YIYoshikazu Ito
Yoshikazu Ito
KMKeisuke Miyazawa
Keisuke Miyazawa
YKYukihiko Kimura
Yukihiko Kimura
KOKazuma Ohyashiki
Kazuma Ohyashiki

12 February 2005 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
NYNoritaka Yamaguchi
Noritaka Yamaguchi
YIYoshikazu Ito
Yoshikazu Ito
KOKazuma Ohyashiki
Kazuma Ohyashiki

15 November 2000 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
YIYoshikazu Ito
Yoshikazu Ito
YKYoshikazu Kawanishi
Yoshikazu Kawanishi
NSNahoko Shoji
Nahoko Shoji
KOKazuma Ohyashiki
Kazuma Ohyashiki
We used flow cytometry to measure the activities of cathepsin G and elastase. The activity of elastase in neutrophils from patients with myelodysplas

6 September 2012 in International Journal of Hematology
Verified
Journal Article
Closed access
PDF file
YIYoshikazu Ito
Yoshikazu Ito
AWAtsushi Wakita
Atsushi Wakita
STSatoru Takada
Satoru Takada
MMMasahiro Mihara
Masahiro Mihara
MGMoritaka Gotoh
Moritaka Gotoh
TNTomoki Naoe
Tomoki Naoe

27 August 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
SKSeiichiro Katagiri
Seiichiro Katagiri
DADaigo Akahane
Daigo Akahane
SOShunsuke Otsuki
Shunsuke Otsuki
ASArisa Suto
Arisa Suto
AYAkiko Yamada
Akiko Yamada
AGAkihiko Gotoh
Akihiko Gotoh
We performed a prospective observational study of chronic myeloid leukemia (CML) patients after anti-SARS-CoV-2 BNT162b2 vaccination (VC). In total, 32 CML patients with tyrosine kinase inhibitor (TKI) therapy, 10 CML patients with treatment-free remission, and 16 healthy subjects participated in the study. From April 2021 to September 2021, all cases (median age = 58 years) were vaccinated twice. Immunoglobulin G for SARS-CoV-2 spike protein (S-IgG) was measured at three timepoints (before the first VC, 1–5 weeks after the second VC (T1), and approximately 6 months after the second VC (T2)). S-IgG was not observed before the first VC in any participant. At T1, all cases had acquired S-IgG. There were no significant differences in S-IgG levels among groups. A paired sample comparison of median S-IgG titers between T1 and T2 in all groups showed a significant reduction in T2 S-IgG titers. There were no significant differences in S-IgG levels among groups. When all patients were analyzed, those aged ≥58 years had significantly lower S-IgG levels than those aged <58 years at T1. The BNT162b2 vaccine was highly effective in CML patients with or without TKIs, and S-IgG levels were as persistent as those in healthy individuals.